Cell Signaling Technology, Inc. Announces Introduction of Antibody Important to Breast Cancer Research
Published: Aug 27, 2013
DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors. Although HER2 has been intensively studied for over 20 years, only recently has it come to light that HER3 may be required for HER2 transformation of normal cells1,2 in at least a subset of cancers. Preclinical research has also recently shown that HER3 activity may be a mechanism by which tumor cells escape inhibition3.
Help employers find you! Check out all the jobs and post your resume.